US Peptide Science Research Team
July 4, 2026
On July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, an 18-month demonstration program designed to expand access to glucagon-like peptide-1 (GLP-1) receptor agonist medications for eligible Medicare Part D beneficiaries. According to cms.gov, the program operates as a temporary bridge to the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model, which is scheduled to integrate GLP-1 coverage into Medicare Part D beginning January 1, 2027.
Unlike standard Part D coverage, the Medicare GLP-1 Bridge functions outside the traditional Part D benefit structure. As documented by cms.gov, participating manufacturers provide eligible GLP-1 drugs at a negotiated net price of $245 per monthly supply, and CMS operates a centralized claims processor to manage prior authorization, adjudication, and pharmacy payments—rather than individual Part D plans handling these functions.
To access GLP-1 medications through the Medicare GLP-1 Bridge, beneficiaries must meet the following enrollment criteria, as specified by cms.gov:
Beneficiaries in Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), and the Limited Income Newly Eligible Transition (LI NET) program are also eligible. However, beneficiaries enrolled in private fee-for-service plans, section 1876 cost contract plans, PACE organizations, fallback plans, and religious fraternal benefit plans are eligible unless they are also enrolled in a standalone PDP.
According to cms.gov, the Medicare GLP-1 Bridge establishes three distinct eligibility pathways based on BMI and comorbid conditions. A provider must attest that the beneficiary meets one of the following:
Pathway 1: BMI ≥35 (no comorbidity requirement)
Pathway 2: BMI ≥30 with specific chronic conditions
Pathway 3: BMI ≥27 with cardiovascular or metabolic conditions
Crucially, as documented by cms.gov, the program is not available for beneficiaries whose primary indication is type 2 diabetes management, obstructive sleep apnea treatment, or metabolic-associated fatty liver disease (MASH). These conditions may be covered under standard Part D benefits through alternative mechanisms.
As of the program launch, according to cms.gov, the following GLP-1 medications are available through the Medicare GLP-1 Bridge when prescribed for weight management:
These medications are approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The program requires that prescribers attest that the medication is prescribed to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification, including structured nutrition and physical activity consistent with the applicable FDA-approved label.
According to cms.gov, eligible beneficiaries pay a flat $50 monthly copay for each 30-day supply of an eligible GLP-1 medication, regardless of which medication is dispensed or the phase of the Part D benefit cycle the beneficiary is in (deductible, initial coverage, coverage gap, or catastrophic coverage).
A critical distinction of the Medicare GLP-1 Bridge is that the copay structure operates entirely outside standard Part D accounting, as detailed by cms.gov:
This structure is intentional: because the program operates outside Part D's benefit architecture, costs under the Medicare GLP-1 Bridge are administratively separated from each beneficiary's Part D plan deductible and out-of-pocket maximum.
When a healthcare provider prescribes an eligible GLP-1 medication to a beneficiary for a use covered under the Medicare GLP-1 Bridge, the provider submits a prior authorization request to a centralized processor designated by CMS, not to the beneficiary's Part D plan. According to cms.gov, CMS contracted with Humana as the central processor for the Medicare GLP-1 Bridge.
The centralized processor manages:
Additional operational details regarding the specific submission portal and timeline for prior authorization request processing are available through cms.gov.
If a provider prescribes a GLP-1 medication to a beneficiary for a different indication (e.g., Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, or Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight), the prior authorization request goes through the beneficiary's Part D plan directly, not the centralized processor. These uses may be covered under standard Part D benefits and would follow traditional Part D utilization management requirements.
According to cms.gov, the Medicare GLP-1 Bridge is nationwide and available in all U.S. states and territories. However, not all Medicare beneficiaries have access, as enrollment in an eligible plan type is required:
Eligible plan types:
Ineligible plan types:
Dually-eligible beneficiaries (enrolled in both Medicare and Medicaid) who are also enrolled in an eligible Part D plan type and meet the clinical criteria are eligible to participate.
The Medicare GLP-1 Bridge is explicitly designed as a temporary pathway. According to cms.gov, to maintain access to GLP-1 medications for weight management in 2027 and beyond, beneficiaries participating in the Bridge must enroll in a Part D plan that has opted to participate in the BALANCE Model for 2027.
Beneficiaries will need to actively select a BALANCE-participating plan during the 2026 Annual Enrollment Period (October–December 2026) to ensure continuity of coverage beginning January 1, 2027.
According to cms.gov, the Medicare GLP-1 Bridge operates under Section 402(a)(1)(A) of the Social Security Amendments of 1967, as amended and made applicable to Part D by Section 1860D-42(b) of the Social Security Act. This authority permits the Secretary of Health and Human Services to conduct demonstration projects to evaluate whether changes in payment or reimbursement methods would improve efficiency and economy of Medicare-covered services.
The demonstration is authorized to run from July 1, 2026, through December 31, 2027—an 18-month period during which CMS will collect utilization data on GLP-1 prescribing patterns and program administration to inform the design of the permanent BALANCE Model in Medicare Part D.
Q: Does the Medicare GLP-1 Bridge cover GLP-1 medications for type 2 diabetes management?
No. According to cms.gov, the Medicare GLP-1 Bridge is exclusively for weight management in beneficiaries who do not have a medically covered indication for GLP-1 therapy through standard Part D benefits. Beneficiaries with type 2 diabetes whose providers prescribe GLP-1 medications for glycemic control should work with their Part D plans to determine coverage under standard Part D benefits.
Q: Can I use the Medicare Prescription Payment Program (MPPP) to spread my $50 copay across the year?
No. According to cms.gov, because the Medicare GLP-1 Bridge operates outside standard Part D coverage, copays under the program are not eligible for MPPP. Beneficiaries must pay the full $50 copay at each monthly dispensing.
Q: If I am on low-income subsidies, will they help reduce my $50 copay?
No. According to cms.gov, low-income cost-sharing subsidies do not apply to any portion of the $50 copay under the Medicare GLP-1 Bridge.
Q: What happens if my prior authorization is denied?
If a prior authorization request is denied, the beneficiary and provider will be notified of the reason for denial. Providers may resubmit with additional clinical information if the initial denial was based on incomplete documentation.
Q: How many Medicare beneficiaries are estimated to be eligible?
Based on analysis of 2023 Part D enrollment data, approximately 3.8 million Medicare beneficiaries are estimated to meet the clinical and BMI criteria for the Medicare GLP-1 Bridge, according to aarp.org.
GLP-1 receptor agonists have emerged as a significant pharmacological approach to weight management over the past decade. These medications work by activating GLP-1 receptors in the hypothalamus and other central nervous system regions involved in appetite regulation, as well as slowing gastric emptying and enhancing satiety signaling.
Research suggests that GLP-1 agonists produce weight reductions in clinical trial populations when combined with lifestyle intervention. Tirzepatide (Zepbound), a GIP/GLP-1 receptor agonist, has demonstrated weight reductions in Phase 3 trials when dosed at higher maintenance levels.
Beyond weight reduction, observational and mechanistic research has identified potential cardiovascular and metabolic benefits associated with GLP-1 agonist therapy, including improvements in blood pressure, lipid profiles, and inflammatory markers. However, the Medicare GLP-1 Bridge program is specifically authorized for weight management in the indicated populations, and clinical decision-making regarding use in individual beneficiaries remains the responsibility of the prescribing provider.
The Medicare GLP-1 Bridge represents a significant expansion of access to GLP-1 medications for Medicare beneficiaries meeting specific clinical criteria. With an estimated 3.8 million eligible beneficiaries and nationwide availability, the program provides a lower-cost pathway ($50 monthly copay) to medications previously available at substantially higher out-of-pocket costs. Beneficiaries should work with their healthcare providers to determine eligibility and initiate prior authorization through the centralized CMS processor, and should plan to enroll in a BALANCE-participating plan for 2027 to maintain continuity of coverage.
Key takeaways: